Daewoong Pharmaceutical’s Nabota, launched in Malaysia… ‘High-quality battle’ in Southeast Asian market
- Full-scale entry with ‘quality power’ proven in global markets such as the US and Europe
- Rapidly growing beauty and plastic surgery market in Malaysia, focusing on millennials
- “We will grow into Southeast Asia’s No. 1 toxin with ‘quality power’ proven in the global market”
Daewoong Pharmaceutical’s Nabota, which has grown into a major toxin with a reputation for ‘high quality’ in the global market, is making a surprise entry into the Malaysian market.
Daewoong Pharmaceutical (CEO Park Sung-soo and Lee Chang-jae) announced on the 30th that it has officially launched its botulinum toxin product ‘Nabota’ in Malaysia. The launch capacity is 100 units.
Malaysia is known as the country with the most difficult pharmaceutical market entry in Southeast Asia, as its pharmaceutical management and supervision are strictly managed in line with global standards such as the US and Europe. Daewoong Pharmaceutical’s botulinum toxin Nabota, which has received approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is the first botulinum toxin from an Asian pharmaceutical company to be launched in Malaysia based on its unrivaled quality recognized in the global market.
Daewoong Pharmaceutical previously received product approval for Nabota from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) in August of last year.